So that is impressive
Sikiric et al., 1999)
Eleven brands across six molecules, made almost entirely by two companies Novo Nordisk and Eli Lilly: Semaglutide (Novo Nordisk) Ozempic, Wegovy, Rybelsus Tirzepatide (Eli Lilly) Mounjaro, Zepbound Liraglutide (Novo Nordisk) Victoza, Saxenda Dulaglutide (Eli Lilly) Trulicity Exenatide (AstraZeneca) Byetta, Bydureon BCise Lixisenatide (Sanofi) Adlyxin, no longer marketed in the US For weight management , the FDA has approved Wegovy, Zepbound and Saxenda
The higher doses also bring the possibility of temporary side effect recurrence
The GLP-1 category is approaching another important inflection point, driven mainly by the launch of oral therapies and the expansion of Medicare access in the U.S., says Terence Flynn, who leads coverage of U.S
Frontiers in immunology, 14, 1110001